How much does tucatinib/tucatinib cost per month?

Tucatinib (Tucatinib) is an oral HER2-targeted small molecule inhibitor developed by the American company Seagen. It is mainly used to treat patients with HER2-positive breast cancer and brain metastases. Its characteristic is that it can highly selectively inhibit the HER2 receptor signaling pathway, while having a weak inhibitory effect on HER1 (EGFR), thus reducing the incidence of side effects such as rash and diarrhea. In treatment, tucatinib is often used in combination with trastuzumab and capecitabine, and has been included in the standard regimen for HER2-positive metastatic breast cancer in Europe and the United States. According to the recommended dosage in the instructions, take 300 mg orally twice a day and continue to use it until disease progression or unacceptable toxicity occurs. Due to the long-term use of drugs, drug prices have become a practical issue that patients are most concerned about.

In the European market, the original drug tucatinib (150mg 84 tablets) is priced at about 40,000 yuan. Calculated based on the recommended dose, the cost of a one-month course of treatment is about 80,000 yuan. This price is affected by many factors, including exchange rate changes, regional tax rates, distribution channels and pharmaceutical company pricing strategies. However, in Asia, especially in countries where it has not yet been launched, patients mostly rely on overseas drug purchase channels, where prices fluctuate greatly and the supply cycle is limited.

It is worth noting that some regions have launched generic versions of tucatinib, such as the 150mg 60-tablet generic drug produced by a Laos pharmaceutical factory. Each box sells for only about 2,000 yuan, which is a significant price drop compared to the original drug. Although the ingredients, dosage and efficacy of generic drugs are basically the same as those of original drugs, it is still recommended that patients use them through formal channels and under the guidance of doctors to ensure stable efficacy and safety. As the clinical value of tucatinib is further recognized, multiple pharmaceutical companies around the world are developing generic versions of it. Prices are expected to gradually decline in the coming years as patent expirations and generic competition increase. For patients with HER2-positive breast cancer, this means there will be more economically feasible treatment options.

Reference materials:https://www.tukysa.com/